5 Undervalued Biotechnology & Medical Research Stocks for Wednesday, September 20
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Wednesday, September 20 based on AAII’s Stock Grades.Pratham Shah
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Commentary & Analysis
6 Undervalued Biotechnology & Medical Research Stocks for Thursday, May 25
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Thursday, May 25 based on AAII’s Stock Grades.Jack Gilleland
Is Geovax Labs Inc's (GOVX) Stock a Good Investment?
Learn more about Geovax Labs Inc’s (GOVX) stock grades for Momentum, Estimate Revisions and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Jenna Brashear
Financial Summary
| Share Statistics | GOVX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1.4 | $214.3 | 1% |
|
| Shares Out (Mil) | 4.6 | 53.9 | 14% |
|
| Institutional Ownership | 60.2% | 92.9% | 39% |
|
| Float (Mil) | 8.5 | 41.4 | 17% |
|
| Beta | 3.69 | 0.96 | 99% |
|
| Avg Daily Volume (000s) | 296 | 506 | 50% |
|
| Price Change (52-week) |
(98.8%) | 43.9% | 2% |
|
| Growth | GOVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.8% | 13.2% | 45% |
|
| Net Income (5yr) | (48.3%) | (10.1%) | 7% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GOVX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($20) | ($44) | 23% |
|
| EPS (TTM) | ($8.754) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | ($34) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | ($1) | $172 | 4% |
|
| Valuation | GOVX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.66 | 2.00 | 15% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GOVX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (408.8%) | (47.5%) | 1% |
|
| ROE | (891.6%) | (53.3%) | 0% |
|
| Liabilities to Assets | 62.1% | 29.6% | 57% |
|
| F-Score | 2 | 2 | 7% |
|
GeoVax Labs, Inc. did not pass any screens on 11/5/2026.
